3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
19
Lymphoma, Mantle-Cell
9
Lymphoma, Non-Hodgkin
4
Multiple Myeloma
3
Lymphoma, Large B-Cell, Diffuse
3
Waldenstrom Macroglobulinemia
2
Recurrence
2
Pancreatic Neoplasms
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Squamous Cell Carcinoma of Head and Neck
1
Pyloric Stenosis, Hypertrophic
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Lymphoma, B-Cell
1
Leukemia, Prolymphocytic
1
Leukemia, Hairy Cell
1
Leukemia
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Glioblastoma
1
DLBCL
1
Chromosome 17 deletion
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Anemia, Hemolytic, Autoimmune
1
Advanced Haematological Malignancies
1
Interventions
pembrolizumab
26
atezolizumab
14
Nivolumab
13
Gemcitabine
13
Cisplatin
10
Docetaxel
8
Carboplatin
8
avelumab
7
Mitomycin
7
epacadostat
4
cabozantinib
4
Ipilimumab
4
pemigatinib
3
Specimen Handling
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Bevacizumab
3
vofatamab
2
rucaparib
2
lenvatinib
2
enfortumab vedotin
2
durvalumab
2
cabazitaxel
2
bempegaldesleukin
2
Standard of Care
2
Rogaratinib
2
Ramucirumab
2
Radiation
2
Platinum
2
Pemetrexed
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Transitional Cell
×
acalabrutinib
×
Clear all
NCT02351739
2019-09-10
KEYNOTE143
Acerta Pharma BV
Phase 2
Completed
78 enrolled
10 charts